Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030
Education & Training
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
TX State Medical License 2012 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Start of enrollment: 2019 Aug 28
Roles: Contact, Principal Investigator
- Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Start of enrollment: 2017 Apr 24
Roles: Contact, Principal Investigator
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsHyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple M...B R Shank, B Primeaux, E K Yeung, S B Horowitz, I Y Lee
Clinical Lymphoma, Myeloma & Leukemia. 2023-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
